Comparative Genomic Characterization of Small Cell Carcinoma of the Bladder Compared With Urothelial Carcinoma and Small Cell Lung Carcinoma

作者：Salvador Jaime‐Casas, Neal Shiv Chawla, Nicholas Salgia, Benjamin Mercier, Ameish Govindarajan, Xiaochen Li, Daniela V. Castro, Hedyeh Ebrahimi, Regina Barragán-Carrillo, Peter D. Zang, Alexis LeVee, Miguel Zugman, Nazlı Dizman, JoAnn Hsu, Luís Meza, Zeynep Büşra Zengin, Alex Chehrazi‐Raffle, Tanya B. Dorff, Sumanta K. Pal, Abhishek Tripathi · 发表于：JCO Precision Oncology · 年份：2025 · DOI：10.1200/po-24-00947 · 被引用次数：2 · 研究领域：Neuroendocrine Tumor Research Advances、Lung Cancer Research Studies、Bladder and Urothelial Cancer Treatments

PURPOSE Small cell bladder cancer (SCBC) is a rare histologic variant of bladder cancer with an aggressive disease course and poor outcomes. Given its uncommon nature, there is a paucity of high-quality data characterizing genomic drivers of this disease, and most patients are treated with approaches mirroring small cell lung cancer (SCLC). Leveraging the Tempus Lens deidentified clinically annotated genomic data set, we sought to evaluate the mutational landscape of SCBC relative to urothelial carcinoma (UC) and SCLC. METHODS Somatic pathogenic genomic alterations in patients with SCBC, UC, and SCLC of any stage who underwent blood- or tissue-based genomic profiling through the Tempus assay were cataloged. Baseline clinical and demographic features were compared across histologic groups. Alterations were collated and summarized using descriptive statistics. Pairwise comparisons were performed to assess differences in mutation frequency across pathologic cohorts. RESULTS In total, 149 SCBC, 4,350 UC, and 1,697 SCLC patients were included in the study. The most common genomic alterations in SCBC were in TP53 (87%), TERT (75%), and RB1 (70%). Among SCBC patients with TP53 mutations, RB1 comutations were observed in 77% of patients. Compared with UC, SCBC patients were significantly enriched for TP53 , RB1 , KMT2D , and KDM6A mutations. Compared with SCLC, SCBC patients were enriched for TERT , ARID1A , and CREBBP mutations, among others ( P < .05). Multiple clinically target...